Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBEX: EMP22 PD and EMP16 PK vs Xenical in Healthy Volunteers
NCT06013163Phase 1Recruiting
- Sponsor
- Empros Pharma
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of orlistat and EMP16 in obesity and Overweight (2 arms), sponsored by Empros Pharma. Primary endpoint: Percent of faecal fat excretion at Day 10. Started Sep 2023; status: recruiting.
02
Drugs
orlistatEMP16
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06013163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013163.